MedPath

Evaluation of the Effect of Genetic Polymorphisms in ERCC1 and OCT2 on the Occurrence and Severity of Cisplatin-induced Nephrotoxicity

Conditions
Cisplatin Adverse Reaction
Interventions
Genetic: ERCC1
Genetic: OCT2
Registration Number
NCT05247671
Lead Sponsor
Ain Shams University
Brief Summary

Approximately one-third of all patients treated with cisplatin develop renal dysfunction after a single dosage of cisplatin. Germline genetic polymorphisms may cause variations in cisplatin pharmacokinetics and in the ability of epithelial kidney cells to take up cisplatin and repair cisplatin-induced Deoxyribonucleic Acid (DNA) damage. Knowledge concerning which genotypes are associated with cisplatin-induced nephrotoxicity may help to identify at-risk patients and initiate strategies, such as using lower or fractionated cisplatin doses or avoiding cisplatin altogether, to prevent Acute Kidney Injury (AKI).

Detailed Description

Approximately one-third of all patients treated with cisplatin develop renal dysfunction after a single dosage of cisplatin. Germline genetic polymorphisms may cause variations in cisplatin pharmacokinetics and in the ability of epithelial kidney cells to take up cisplatin and repair cisplatin-induced DNA damage. Knowledge concerning which genotypes are associated with cisplatin-induced nephrotoxicity may help to identify at-risk patients and initiate strategies, such as using lower or fractionated cisplatin doses or avoiding cisplatin altogether, to prevent AKI.

Patient written informed consent will be taken prior to study conductance

1. Full laboratory evaluation before and after cisplatin administration including:

(Complete Blood Count) CBC, liver and renal functions. glomerular filtration rate (GFR), and estimated glomerular filtration rate (eGFR) Serum electrolytes. Marker of nephrotoxicity: Cystatin C.

2. Sample Collection and single nucleotide polymorphism (SNP) Genotyping:

Venous blood (2 mL) will be collected from each subject into tubes containing 50 mmol of Ethylenediamine tetraacetic acid (EDTA) per liter and genomic DNA will be isolated with the GeneJET Whole Blood Genomic DNA purification Mini kit, according to manufacturer's instructions. Polymorphisms will be assessed using the TaqMan based real-time polymerase chain reaction (PCR) assay.

This study aims to assess the influence of single nucleotide polymorphisms in the DNA repair gene Excision Repair Cross Complementation group 1 (ERCC1) and Cisplatin uptake transporter gene Organic Cation Transporter 2 (OCT2) on cisplatin-induced nephrotoxicity by assessment of the following:

1. Occurrence of nephrotoxicity.

2. Degree of renal impairment.

3. Changes in traditional and novel protein biomarkers for AKI.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
89
Inclusion Criteria
  • Males or females aged >18 years receiving cisplatin-containing chemotherapy.
  • A Cisplatin dose starting from 75 mg/m2
  • Various cancer types
  • No history of organ transplantation or kidney dialysis.
  • Patients with normal renal function
Read More
Exclusion Criteria
  • Co-administration of ifosfamide with cisplatin, because of the known risk of nephrotoxicity.
  • Pregnant or lactation.
  • Infection with the human immunodeficiency virus (HIV).
  • Prior administration of cisplatin.
  • Intraperitoneal chemotherapy.
  • Inadequate liver function (bilirubin > 1.5 times upper normal limit (UNL) and alanine transaminase (ALT) or aspartate transaminase (AST) > 3.0 UNL or up to 5.0 UNL in the presence of hepatic metastases).
  • Inadequate renal function (creatinine > 1.25 times UNL, creatinine clearance < 50 mL/min).
  • Serious comorbid systemic disorder incompatible with the study (uncontrolled diabetes mellitus (DM) or hypertension (HTN), myocardial infarction within the last 6 months).
  • Patients diagnosed with kidney cancer.
  • Exposure to any nephrotoxic drugs or agents.
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
CaseOCT2All eligible patients will be recruited to the study and will be assessed for SNPs in both ERCC1 and OCT2 and their association with cisplatin-induced nephrotoxicity through the measurement of cystatin C before taking cisplatin and after receiving the second cycle of cisplatin.
CaseERCC1All eligible patients will be recruited to the study and will be assessed for SNPs in both ERCC1 and OCT2 and their association with cisplatin-induced nephrotoxicity through the measurement of cystatin C before taking cisplatin and after receiving the second cycle of cisplatin.
Primary Outcome Measures
NameTimeMethod
Serum CreatinineChange from baseline at the end of cycle 2 (each cycle is 28 days)

available in patient profile

Secondary Outcome Measures
NameTimeMethod
cystatin cChange from baseline at the end of cycle 2 (each cycle is 28 days)

measured by Human cystatin C ELISA kit

Trial Locations

Locations (1)

Faculty of medicine, Ain Shams University

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath